Deals

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease
Abogen BiosciencesmRNA

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease

Abogen Biosciences Co., Ltd. ("Abogen"), a clinical‑stage biotechnology group pioneering RNA innovation, announced that it has entered into a licensing and option agreement with Novartis AG (NYSE: NVS) to advance…

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Xinzeyuan Medical Raises Series B+ Funding for Surgical Supply Chain
Xinzeyuan Medical Technology

Xinzeyuan Medical Raises Series B+ Funding for Surgical Supply Chain

IVIEW Therapeutics Secures Series A++ Funding for Ophthalmology Pipeline
FinanceIVIEW Therapeutics

IVIEW Therapeutics Secures Series A++ Funding for Ophthalmology Pipeline

Daiichi Sankyo Acquires Gatipotuzumab IP Rights for $132.5M
ADC / XDCDaiichi Sankyo

Daiichi Sankyo Acquires Gatipotuzumab IP Rights for $132.5M

a16z Bio + Health Launches Biotech Ecosystem Venture Fund
Andreessen Horowitz (a16z) Bio + HealthFinance

a16z Bio + Health Launches Biotech Ecosystem Venture Fund

Show More